The Inflammation Laboratory (LABINFLA) of the Instituto Oswaldo Cruz (IOC/Fiocruz) has been operating since 1989 in the generation of knowledge, products and scientific-technological innovation in the areas of pharmacology and medicinal chemistry, as well as in the training of high-level scientists and technicians in the field of pharmacological control of the inflammatory response, aiming at the treatment of inflammatory diseases pulmonary disorders, metabolic alterations and cancer. 

The Laboratory's work is guided by studies aimed at generating knowledge in the field of modeling respiratory, metabolic and neuro-degenerative diseases, pharmacological control of inflammation and lung remodeling, as well as the training of higher-level human resources in the area of ​​science and technology, aiming to meet the health needs of the Brazilian population.  

Prospective and preclinical studies of new drug candidates are carried out in models in vivo, ex vivo and / or vitro of obstructive and restrictive lung diseases, including asthma, silicosis, chronic obstructive pulmonary disease, and, more recently, Influenza and Covid-19. 

New investigational compounds, therapeutic targets and safer and more effective alternative treatments are also studied. The team acts in the evaluation of bioactive substances of synthetic and natural origin, in addition to nanostructured systems with therapeutic potential.  

Head of the Inflammation Laboratory
Marco Aurelius Martins (Curriculum lattes) 

Deputy Head of the Inflammation Laboratory 
Vinícius de Frias Carvalho (Curriculum lattes)